Cisco Collaboration Flex Plan Sample Clauses

Cisco Collaboration Flex Plan. A Cisco Collaboration Flex Plan subscription allows You to flexibly deploy various Cisco-hosted software-as- a-service offerings (“Cloud Services”) and licensed software (“Software”) for on-premises or partner-hosted deployments. Cloud Services offered in the plan include: Webex Meetings, Webex Calling, Webex Calling (formerly Cisco Spark Call), Webex Calling for SP, UCM Cloud Calling, Webex Teams, Cisco FedRAMP Webex Meetings, and Unified Communications Manager Cloud for Government. In an on-premises or partner- hosted deployment, Cisco offers the following Software: Cisco Meeting Server, Cisco Unified Communications Manager, and HCS. Note that when You choose an on-premises or partner-hosted deployment, You will also receive Webex Teams (a Cloud Service). The Cloud Services and Software are available under license models for named user (customer is obligated to pay per user), active user (customer is obligated to pay for actual usage), enterprise agreement (customer is obligated to pay for enterprise-wide use), or shared meetings (customer is obligated to pre-purchase a fixed number of meetings). Each license model is further described in Section 2 of this Offer Description and reflected on the Order You place with Your Approved Source. Note: This Offer Description also applies to the Cisco Collaboration Spark Flex Plan.
Sample 1
AutoNDA by SimpleDocs
Cisco Collaboration Flex Plan. A Cisco Collaboration Flex Plan subscription allows You to flexibly deploy various Cisco Technology for Cisco- hosted, on-premises or partner-hosted deployments. Cloud Services offered in the plan include: Webex Meetings, Webex Calling, Webex Calling (formerly Cisco Spark Call), Webex Calling for SP, Unified Communications Manager Cloud, Webex app, Cisco FedRAMP Webex Meetings, and Unified Communications Manager Cloud for Government. In an on-premises or partner-hosted deployment, Cisco may offer the following Software: Cisco Meeting Server, Cisco Unified Communications Manager, and HCS. Controlled Doc. # EDCS-13324740 Ver: 7.7 Last Modified: Sat Dec 26 07:56:38 PST 2020 CISCO PUBLIC INFORMATION, cisco_collaboration_flex_plan.docx Note that when You choose an on-premises or partner-hosted deployment, You will also receive Webex app (a Cloud Service). The Cisco Technology may be available under one or more of the following license models: Named User (customer is obligated to pay per user); Active User (customer is obligated to pay for actual usage); Enterprise Agreement (customer is obligated to pay for enterprise-wide use); or Shared Meetings (customer is obligated to pre-purchase a fixed number of meetings). Each license model is further described in Section 2 below and reflected on the rder You place with Your Approved Source. This Offer Description also applies to the Cisco Collaboration Spark Flex Plan, as well as all versions of the Cisco Collaboration Flex Plan offer.
Sample 1
Cisco Collaboration Flex Plan. A Cisco Collaboration Flex Plan subscription allows You to flexibly deploy various Cisco Technology for Cisco- hosted, on-premises or partner-hosted deployments. Cloud Services offered in the plan include: Webex Meetings, Webex Calling, Webex Calling (formerly Cisco Spark Call), Webex Calling for SP, Unified Communications Manager Cloud, Webex app, Webex Webinars (formerly Webex Events), Webex Video Integration for Microsoft Teams, Cisco FedRAMP Webex Meetings, and Unified Communications Manager Cloud for Government. In an on-premises or partner-hosted deployment, Cisco may offer the following Software: Cisco Meeting Server, Cisco Unified Communications Manager, and HCS. Note that when You choose an on-premises or partner-hosted deployment, You will also receive Webex app (a Cloud Service).
Sample 1

Related to Cisco Collaboration Flex Plan

  • AREAS OF COLLABORATION The School will collaborate under Xxxx Innovation Mission to establish, operate and support ATL in India within the school premises with financial support from NITI Aayog.

  • Develop programs 1) The Employer will develop and implement health promotion and health education programs, subject to the availability of resources. Each Appointing Authority will develop a health promotion and health education program consistent with the Minnesota Management & Budget policy. Upon request of any exclusive representative in an agency, the Appointing Authority shall jointly meet and confer with the exclusive representative(s) and may include other interested exclusive representatives. Agenda items shall include but are not limited to smoking cessation, weight loss, stress management, health education/self-care, and education on related benefits provided through the health plan administrators serving state employees.

  • Commercialization Intrexon shall have the right to develop and Commercialize the Reverted Products itself or with one or more Third Parties, and shall have the right, without obligation to Fibrocell, to take any such actions in connection with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

  • Development Plan document specifying the work program, schedule, and relevant investments required for the Development and the Production of a Discovery or set of Discoveries of Oil and Gas in the Contract Area, including its abandonment.

  • SOURCE CODE ESCROW FOR LICENSED PRODUCT If Source Code or Source Code escrow is offered by either Contractor or Product manufacturer or developer to any other commercial customers, Contractor shall either: (i) provide Licensee with the Source Code for the Product; or (ii) place the Source Code in a third party escrow arrangement with a designated escrow agent who shall be named and identified to the State, and who shall be directed to release the deposited Source Code in accordance with a standard escrow agreement acceptable to the State; or (iii) will certify to the State that the Product manufacturer/developer has named the State, acting by and through the Authorized User, and the Licensee, as a named beneficiary of an established escrow arrangement with its designated escrow agent who shall be named and identified to the State and Licensee, and who shall be directed to release the deposited Source Code in accordance with the terms of escrow. Source Code, as well as any corrections or enhancements to such source code, shall be updated for each new release of the Product in the same manner as provided above and such updating of escrow shall be certified to the State in writing. Contractor shall identify the escrow agent upon commencement of the Contract term and shall certify annually that the escrow remains in effect in compliance with the terms of this clause. The State may release the Source Code to Licensees under this Contract who have licensed Product or obtained services, who may use such copy of the Source Code to maintain the Product.

  • Development Activities The Development activities referred to in item “b” of paragraph 3.1 include: studies and projects of implementation of the Production facilities; drilling and completion of the Producing and injection xxxxx; and installation of equipment and vessels for extraction, collection, Treatment, storage, and transfer of Oil and Gas. The installation referred to in item “c” includes, but is not limited to, offshore platforms, pipelines, Oil and Gas Treatment plants, equipment and facilities for measurement of the inspected Production, wellhead equipment, production pipes, flow lines, tanks, and other facilities exclusively intended for extraction, as well as oil and gas pipelines for Production Outflow and their respective compressor and pumping stations.

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Collaboration We believe joint effort toward common goals achieves trust and produces greater impact for L.A. County’s youngest children and their families.

  • Clinical Trials The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company, or in which the Company has participated, that are described in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, or the results of which are referred to in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus, were and, if still pending, are being conducted in all material respects in accordance with protocols, procedures and controls pursuant to, where applicable, accepted professional and scientific standards for products or product candidates comparable to those being developed by the Company and all applicable statutes, rules and regulations of the FDA, the EMEA, Health Canada and other comparable drug and medical device (including diagnostic product) regulatory agencies outside of the United States to which they are subject; the descriptions of the results of such studies, tests and trials contained in the Registration Statement, the Time of Sale Disclosure Package or the Prospectus do not contain any misstatement of a material fact or omit a material fact necessary to make such statements not misleading; the Company has no knowledge of any studies, tests or trials not described in the Disclosure Package and the Prospectus the results of which reasonably call into question in any material respect the results of the studies, tests and trials described in the Registration Statement, the Time of Sale Disclosure Package or Prospectus; and the Company has not received any notices or other correspondence from the FDA, EMEA, Health Canada or any other foreign, state or local governmental body exercising comparable authority or any Institutional Review Board or comparable authority requiring or threatening the termination, suspension or material modification of any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or in which the Company has participated, and, to the Company’s knowledge, there are no reasonable grounds for the same. Except as disclosed in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus, there has not been any violation of law or regulation by the Company in its respective product development efforts, submissions or reports to any regulatory authority that could reasonably be expected to require investigation, corrective action or enforcement action.

  • For clarity the time allowances provided in clause 2.10 shall operate to reduce the maximum timetabled classroom teaching time specified in clause 4.2 of this agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.